European research study aims to improve treatment for traumatic brain injury

Posted in Industry News,News Review on 8th Jan 2018

 

Source: ICON plc
Published online: 8/1/18


ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has contributed to a complex pan-European traumatic brain injury (TBI) research study involving over 4,500 patients in 65 sites in 20 European countries.

ICON provided site management and source data verification (SDV) services to the study, which was supported by the EU and led by Professor Andrew Maas from the University Hospital Antwerp (Belgium) and Professor David Menon from the University of Cambridge (UK). ICON’s Dr Valérie Legrand, VP Project Management and a recognised expert in CNS, also provided clinical expertise as a member of the project’s Management Committee.

The Lancet Neurology Commission on TBI was launched at the European Parliament on 7th November 2017 and set out clinical and research priorities and recommendations to address the varied challenges in TBI.

The Commission on TBI identifies 12 key recommendations and policies to improve the prevention, quality of care and clinical research in TBI. It seeks to identify strategies to better characterise TBI, increase prognostic accuracy, and adopt a more precision-medicine approach 
to treatments. The Commission also promotes the use of new tools
 for clinical evidence generation and implementation, so that research outputs can be more rapidly integrated into clinical care. Moreover, 
it highlights the importance of international collaboration of funding agencies and researchers to provide a global response to reduce the individual and societal burden of TBI.

Read Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research free online at http://bit.ly/2jbGfst

SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

This website is for medical professionals only.